Skip to content

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

CRCNS US-France Research Proposal: Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05224063
Enrollment
50
Registered
2022-02-04
Start date
2023-01-01
Completion date
2025-03-27
Last updated
2026-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for depression when targeting the dorsolateral prefrontal cortex (dlPFC) of the central executive network (CEN). However, remission rates are suboptimal and individual methods to target the dlPFC are lacking. In this study, we will enroll 50 patients with major depression and in a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design will assess whether rTMS targeted to an individual's central executive network (CEN) assessed by single pulse TMS can enhance network modulation. If successful, this work will lead to a clinical rTMS trial comparing this personalized targeting approach against standard rTMS.

Detailed description

There is a critical need for more effective treatments for depression, which currently affect 20% of Americans during our lifetimes. Brain stimulation treatments, including repetitive transcranial magnetic stimulation (rTMS), represent the front line of innovative approaches by directly targeting and correcting specific dysfunctional brain networks. A core dysfunctional network in major depressive disorder is the fronto-parietal central executive network (CEN), a network critical for decision making and cognitive control. The CEN includes the dorsolateral prefrontal cortex (dlPFC), the target of FDA-cleared rTMS treatment for depression. rTMS to the dlPFC is thought to improve depression by modulating local dlPFC excitability and enhancing downstream CEN connectivity. However, our ability to probe the CEN and study this potential mechanism on an individual basis is critically lacking, likely contributing to suboptimal rTMS remission rates (20-40%). We hypothesize that the CEN connectivity is weakened in depression and can be maximally modulated by individualizing localization. To test this hypothesis, a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design with 50 depressed patients was conducted to characterize the effects of intermittent theta burst stimulation (iTBS) on frontoparietal network excitability. Participants were 18-65 years old and screened to exclude psychiatric or neurological disorders, including moderate or greater depressive symptoms. Participants first underwent MRI scanning to obtain structural brain data for neuronavigation. During the experimental session, intermittent theta burst stimulation (iTBS) was applied to the dlPFC to modulate the CEN. Two stimulation conditions were administered in randomized order: real iTBS and sham iTBS. To probe network-level changes, single-pulse TMS (spTMS) was applied to both the dlPFC and posterior parietal cortex (PPC) before and after iTBS. These probes were interleaved with iTBS in alternating blocks, allowing for repeated assessments of cortical excitability and connectivity across time. TMS-evoked potentials (TEPs) were recorded using EEG to quantify changes in both local (dlPFC) and downstream (parietal cortex) responses. The primary outcome was the change in TMS-evoked EEG responses (e.g., early TEP components) following iTBS. This study design enables characterization of the temporal dynamics and dose-dependent effects of iTBS on human brain networks. Findings from this work provide insight into mechanisms of noninvasive brain stimulation and may inform future efforts to optimize personalized neuromodulation strategies for neuropsychiatric disorders.

Interventions

DEVICENeuronavigated rTMS

Delivers patterned magnetic stimulation based on MRI images

DEVICESham rTMS

Delivers placebo magnetic stimulation

Sponsors

Stanford University
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Men and women, ages 18 to 65 * Depression assessed through in-depth Structured Clinical Interview for DMS-5 (SCID-I) * PHQ9 \> 10 for disease severity * Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales * Right-handed * No current or history of neurological disorders * No seizure disorder or risk of seizures * No use of PRN medication within 24 hours of the scheduled study appointment

Exclusion criteria

* Those with a contraindication for MRIs (e.g. implanted metal) * Any unstable medical condition * History of head trauma with loss of consciousness * History of seizures * Neurological or uncontrolled medical disease * Active substance abuse * Diagnosis of psychotic or bipolar disorder * A prior history of ECT or rTMS failure * Currently taking medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium) * Currently pregnant or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Change in TMS-evoked EEG Responses Following Intermittent Theta Burst Stimulation (iTBS)Pre-intervention and up to 20 minutes post-interventionTMS-evoked EEG responses were measured before and after intermittent theta burst stimulation (iTBS) using single-pulse TMS probes applied to prefrontal and parietal regions. The primary measure was the change in early TMS-evoked potentials (TEPs), defined as the peak-to-peak amplitude within approximately 20-50 ms following the TMS pulse. Changes in electrophysiological responses were assessed across timepoints (pre-intervention, early post-intervention, and late post-intervention) and compared between active and sham stimulation conditions to characterize modulation of frontoparietal network excitability.

Countries

United States

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
50 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
7 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
22 Participants
Region of Enrollment
United States
50 Participants
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 500 / 50
other
Total, other adverse events
4 / 504 / 50
serious
Total, serious adverse events
0 / 500 / 50

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 16, 2026